Silver Book Fact

A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate
cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in median survival.

Kantoff, P, C Higano, N Shore, E Berger, E Small, D Penson, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. NEJM. 2010; 363: 411-22. http://www.nejm.org/doi/full/10.1056/NEJMoa1001294

Reference

Title
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Publication
NEJM
Publication Date
2010
Authors
Kantoff, P, C Higano, N Shore, E Berger, E Small, D Penson, et al.
Pages
411-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The overall five-year survival rate for women with invasive breast cancer is now 89 percent.  
  • Surgical biopsy for lumps in the breast was found by one study to cost 2 1/2 to 3 times more than image-guided core-needle biopsy ($698 versus $243).  
  • Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months…  
  • A 10 percent reduction in cancer-related deaths in the U.S. would be worth an estimated $4.4 trillion to current and future generations.  
  • Percentage of women age 50 and over who had a mammogram in the past 2 years, by age group, selected years 1987-2005